Masato Fujii, MD

Articles

UFT Plus Carboplatin for Head and Neck Cancer

Masato Fujii, MD;Yoshihiro Ohno, MD;Yutaka Tokumaru, MD;Yorihisa Imanishi, MD;Minoru Kanke, MD;Toshiki Tomita, MD;Taku Yamashita, MD

October 1st 2000

Cisplatin plus fluorouracil (5-FU) is widely accepted as neoadjuvant and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma; UFT is also an active agent against this disease. In the first retrospective study, we examined the efficacy of UFT as adjuvant chemotherapy in patients with maxillary cancer.

Using Preoperative UFT to Predict Sensitivity to Fluoropyrimidines in Colorectal Cancer

Masato Fujii, MD

July 1st 1999

This study was designed to determine if histopathologic evaluation of patients with resectable colorectal cancer following preoperative chemotherapy with uracil and tegafur with a molar ratio of 4:1 (UFT) could predict